Asset Details
Do you wish to reserve the book?
Comparative Study of 250 mg/day Terbinafine and 100 mg/day Itraconazole for the Treatment of Cutaneous Sporotrichosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Comparative Study of 250 mg/day Terbinafine and 100 mg/day Itraconazole for the Treatment of Cutaneous Sporotrichosis
Do you wish to request the book?
Comparative Study of 250 mg/day Terbinafine and 100 mg/day Itraconazole for the Treatment of Cutaneous Sporotrichosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Comparative Study of 250 mg/day Terbinafine and 100 mg/day Itraconazole for the Treatment of Cutaneous Sporotrichosis
2011
Overview
Itraconazole is currently used for the treatment of cutaneous sporotrichosis. Terbinafine at a daily dose of 250 mg has been successfully applied to the treatment of cutaneous sporotrichosis.
Objective
To compare the efficacy of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis.
Materials and methods
A bidirectional cohort study was conducted on 55 patients receiving 250 mg/day terbinafine and 249 patients receiving 100 mg/day itraconazole. The latter patients were matched for age and clinical form to the terbinafine group at a ratio of 5:1.
Sporothrix schenckii
was isolated by culture from all patients (age range: 18–70 years), who were submitted to the standard care protocol consisting of clinical and laboratory evaluation and periodic visits.
Results
Cure was observed in 51 (92.7%) patients of the terbinafine group and 229 (92%) of the itraconazole group within a similar mean period of time (11.5 and 11.8 weeks, respectively). An increase in the terbinafine dose to 500 mg was necessary in two patients due to the lack of a response, and one patient presented recurrence. In the itraconazole group, two patients required a dose increase and three presented recurrence. Adverse events were equally frequent among patients receiving terbinafine (
n
= 4, 7.3%) and itraconazole (
n
= 19, 7.6%) and were generally mild without the need for drug discontinuation, except for two patients of the itraconazole group.
Conclusion
Terbinafine administered at a daily dose of 250 mg is an effective and well-tolerated option for the treatment of cutaneous sporotrichosis.
Publisher
Springer Netherlands,Springer,Springer Nature B.V
Subject
/ Aged
/ Antifungal Agents - administration & dosage
/ Antifungal Agents - adverse effects
/ Biomedical and Life Sciences
/ Drug Administration Schedule
/ Female
/ Fungi
/ Humans
/ Itraconazole - administration & dosage
/ Itraconazole - adverse effects
/ Male
/ Naphthalenes - administration & dosage
/ Naphthalenes - adverse effects
/ Sporothrix - isolation & purification
